Aclaris Therapeutics's three largest insider shareholders as of May 30, 2026 are Braden Michael Leonard (TenPercentOwner, 28.29Mn shares), Neal Walker (Ceo, 1.54Mn shares), Anand Mehra (Director, 714.82K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Andrew N Schiff | - | 0 | 434,455 | 14 Nov, 2022 |
| Vincent Milano | - | 17,316 | 0 | 09 Jun, 2025 |
| Maxine Gowen | - | 21,754 | 0 | 09 Jun, 2025 |
| Andrew Kenneth William Powell | - | 33,523 | 0 | 04 Jun, 2024 |
| Braden Michael Leonard | - | 0 | 28,293,975 | 05 Aug, 2024 |
| Bryan M. Reasons | - | 28,732 | 0 | 04 Jun, 2024 |
| Anand Mehra | - | 714,823 | 0 | 09 Jun, 2025 |
| Neal Walker | Ceo | 1,543,886 | 0 | 05 Feb, 2026 |
| Capital Management Iii, Llc Foresite | - | 0 | 8,276 | 03 Nov, 2021 |
| Kamil Ali-Jackson | Chief Legal Officer | 160,214 | 0 | 05 Jan, 2022 |
| Frank Ruffo | Chief Financial Officer | 201,883 | 0 | 14 Mar, 2022 |
| Christopher P. Molineaux | - | 57,956 | 0 | 09 Jun, 2025 |
| William D. Humphries | - | 33,525 | 0 | 09 Jun, 2025 |
| David N. Gordon | Chief Medical Officer | 147,447 | 0 | 14 Jul, 2021 |
| Gail Cawkwell | Chief Medical Officer | 9,593 | 0 | 05 Jul, 2023 |
| James Loerop | Chief Business Officer | 192,260 | 0 | 05 Feb, 2026 |
| Joseph Monahan | Chief Scientific Officer | 265,662 | 0 | 04 Mar, 2025 |
| Douglas J. Manion | Pres And Ceo | 41,813 | 0 | 03 Jan, 2024 |
| Kevin Balthaser | Chief Financial Officer | 187,453 | 0 | 03 Mar, 2026 |
| Hugh M. Davis | President And Coo | 45,425 | 0 | 05 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Mar, 2026 | Kevin Balthaser | Common Stock | A | 2,375 | - | 188,130 | D | M |
| 01 Mar, 2026 | Kevin Balthaser | Common Stock | A | 2,375 | - | 188,130 | D | M |
| 01 Mar, 2026 | Kevin Balthaser | Common Stock | D | 677 | $2.87 | 187,453 | D | F |
| 01 Mar, 2026 | Kevin Balthaser | Common Stock | D | 677 | $2.87 | 187,453 | D | F |
| 01 Mar, 2026 | Kevin Balthaser | Restricted Stock Units | D | 2,375 | $0.00 | 0 | D | M |
| 01 Mar, 2026 | Kevin Balthaser | Restricted Stock Units | D | 2,375 | $0.00 | 0 | D | M |
| 02 Feb, 2026 | Neal Walker | Restricted Stock Units | A | 274,800 | $0.00 | 274,800 | D | A |
| 02 Feb, 2026 | Roland Wilhelm Kolbeck | Restricted Stock Units | A | 95,700 | $0.00 | 95,700 | D | A |
| 02 Feb, 2026 | Kevin Balthaser | Restricted Stock Units | A | 99,100 | $0.00 | 99,100 | D | A |
| 02 Feb, 2026 | Neal Walker | Restricted Stock Units | A | 274,800 | $0.00 | 274,800 | D | A |
| 02 Feb, 2026 | Jesse Wayne Hall | Restricted Stock Units | A | 98,100 | $0.00 | 98,100 | D | A |
| 02 Feb, 2026 | James Loerop | Restricted Stock Units | A | 97,700 | $0.00 | 97,700 | D | A |
| 02 Feb, 2026 | Kevin Balthaser | Restricted Stock Units | A | 99,100 | $0.00 | 99,100 | D | A |
| 02 Feb, 2026 | Jesse Wayne Hall | Restricted Stock Units | A | 98,100 | $0.00 | 98,100 | D | A |
| 02 Feb, 2026 | Hugh M. Davis | Restricted Stock Units | A | 96,100 | $0.00 | 96,100 | D | A |
| 02 Feb, 2026 | Hugh M. Davis | Restricted Stock Units | A | 96,100 | $0.00 | 96,100 | D | A |
| 02 Feb, 2026 | James Loerop | Restricted Stock Units | A | 97,700 | $0.00 | 97,700 | D | A |
| 02 Feb, 2026 | Roland Wilhelm Kolbeck | Restricted Stock Units | A | 95,700 | $0.00 | 95,700 | D | A |
| 02 Feb, 2026 | Roland Wilhelm Kolbeck | Employee Stock Option (Right to Buy) | A | 334,900 | $0.00 | 334,900 | D | A |
| 02 Feb, 2026 | Jesse Wayne Hall | Employee Stock Option (Right to Buy) | A | 343,300 | $0.00 | 343,300 | D | A |